{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:43:53Z","timestamp":1784735033296,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40268-026-00535-y","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:27:12Z","timestamp":1772087232000},"page":"39-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preclinical Evaluation of AHT-102, a CLDN18.2 \u00d7 CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2768-9288","authenticated-orcid":false,"given":"Huilun","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guili","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niliang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lun","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"23","key":"535_CR1","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1547.","journal-title":"Clin Cancer Res"},{"key":"535_CR2","doi-asserted-by":"publisher","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial [published correction appears in Lancet. 2023 Jul 22;402(10398):290] [published correction appears in Lancet. 2024 Jan 6;403(10421):30]. Lancet. 2023;401(10389):1655\u20131668. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"535_CR3","doi-asserted-by":"publisher","unstructured":"Dong D, Zheng L, Lin J, et al. Structural basis of assembly of the human T cell receptor-CD3 complex [published correction appears in Nature. 2021;590(7846):E52]. Nature. 2019;573(7775):546\u2013-552. https:\/\/doi.org\/10.1038\/s41586-019-1537-0.","DOI":"10.1038\/s41586-019-1537-0"},{"key":"535_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","volume":"154","author":"D Ellerman","year":"2019","unstructured":"Ellerman D. Bispecific t-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods. 2019;154:102\u201317. https:\/\/doi.org\/10.1016\/j.ymeth.2018.10.026.","journal-title":"Methods"},{"issue":"2","key":"535_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020287","volume":"13","author":"J Middelburg","year":"2021","unstructured":"Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T. Overcoming challenges for CD3-bispecific antibody therapy in solid tumors. Cancers (Basel). 2021;13(2):287. https:\/\/doi.org\/10.3390\/cancers13020287.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"535_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2022.152283","volume":"227","author":"G Xu","year":"2022","unstructured":"Xu G, Qian N, Liu Y, et al. Preclinical characterization of a Fab-like CD3\/CLDN18.2 XFab\u00ae bispecific antibody against solid tumors. Immunobiology. 2022;227(6):152283. https:\/\/doi.org\/10.1016\/j.imbio.2022.152283.","journal-title":"Immunobiology"},{"issue":"3","key":"535_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.bbrc.2012.08.017","volume":"425","author":"PJ Fraker","year":"1978","unstructured":"Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun. 1978;425(3):510\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2012.08.017.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"535_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ctrv.2010.03.001","volume":"36","author":"D Seimetz","year":"2010","unstructured":"Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010;36(6):458\u201367. https:\/\/doi.org\/10.1016\/j.ctrv.2010.03.001.","journal-title":"Cancer Treat Rev"},{"issue":"19","key":"535_CR9","doi-asserted-by":"publisher","first-page":"28059","DOI":"10.18632\/oncotarget.8574","volume":"7","author":"J Borlak","year":"2016","unstructured":"Borlak J, L\u00e4nger F, Spanel R, Sch\u00f6ndorfer G, Dittrich C. Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fc\u03b3 receptors. Oncotarget. 2016;7(19):28059\u201374. https:\/\/doi.org\/10.18632\/oncotarget.8574.","journal-title":"Oncotarget"},{"issue":"12","key":"535_CR10","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1007\/s00262-023-03535-y","volume":"72","author":"B Wang","year":"2023","unstructured":"Wang B, Liu Y, Yuan R, et al. XFab-\u03b14-1BB\/CD40L fusion protein activates dendritic cells, improves expansion of antigen-specific T cells, and exhibits antitumour efficacy in multiple solid tumour models. Cancer Immunol Immunother. 2023;72(12):4015\u201330. https:\/\/doi.org\/10.1007\/s00262-023-03535-y.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"535_CR11","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1158\/2326-6066.CIR-19-0121","volume":"7","author":"L Wang","year":"2019","unstructured":"Wang L, Hoseini SS, Xu H, Ponomarev V, Cheung NK. Silencing Fc domains in t cell-engaging bispecific antibodies improves t-cell trafficking and antitumor potency. Cancer Immunol Res. 2019;7(12):2013\u201324. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0121.","journal-title":"Cancer Immunol Res"},{"issue":"22","key":"535_CR12","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","volume":"26","author":"MR Middleton","year":"2020","unstructured":"Middleton MR, McAlpine C, Woodcock VK, et al. Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2020;26(22):5869\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1247.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"535_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/imt-2020-0256","volume":"13","author":"HD Hummel","year":"2021","unstructured":"Hummel HD, Kufer P, Gr\u00fcllich C, et al. Pasotuxizumab, a BiTE\u00ae immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings. Immunotherapy. 2021;13(2):125\u201341. https:\/\/doi.org\/10.2217\/imt-2020-0256.","journal-title":"Immunotherapy"},{"issue":"28","key":"535_CR14","doi-asserted-by":"publisher","first-page":"12605","DOI":"10.1073\/pnas.1000976107","volume":"107","author":"R Lutterbuese","year":"2010","unstructured":"Lutterbuese R, Raum T, Kischel R, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci USA. 2010;107(28):12605\u201310. https:\/\/doi.org\/10.1073\/pnas.1000976107.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"535_CR15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1158\/1535-7163.MCT-17-0657","volume":"17","author":"D Mandikian","year":"2018","unstructured":"Mandikian D, Takahashi N, Lo AA, et al. Relative target affinities of t-cell-dependent bispecific antibodies determine biodistribution in a solid tumor mouse model. Mol Cancer Ther. 2018;17(4):776\u201385. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0657.","journal-title":"Mol Cancer Ther"},{"key":"535_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231217967","volume":"16","author":"Y Kubota","year":"2024","unstructured":"Kubota Y, Shitara K. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer. Ther Adv Med Oncol. 2024;16:17588359231217967. https:\/\/doi.org\/10.1177\/17588359231217967.","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"535_CR17","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"issue":"1","key":"535_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","volume":"17","author":"X Chong","year":"2024","unstructured":"Chong X, Madeti Y, Cai J, et al. Recent developments in immunotherapy for gastrointestinal tract cancers. J Hematol Oncol. 2024;17(1):65. https:\/\/doi.org\/10.1186\/s13045-024-01578-x. (published 2024 Aug 9).","journal-title":"J Hematol Oncol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-026-00535-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:41:59Z","timestamp":1776066119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-026-00535-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["535"],"URL":"https:\/\/doi.org\/10.1007\/s40268-026-00535-y","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in strict compliance with the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals (2020 Edition) and the Laboratory Animal Guidelines for Euthanasia from China (standard number: GB\/T 397602021). Throughout the study, we adhered to the 3R principles, emphasizing the reduction in the number of animals used, the replacement of animals where possible, and the refinement of experimental conditions and procedures to minimize distress or pain. The number of animals, experimental design, and animal handling were approved by the Institutional Animal Care and Use Committee (IACUC) of Hubei Tianqin Xinshi Biotechnology Co., Ltd. (Approval No.: IACUC-A2022011-T011-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable. This study did not involve human participants; human peripheral blood mononuclear cells used in this study were obtained from commercial sources.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The authors declare that they have no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Conception and design: Huilun Chu, Junping Lv, Haifeng Song. Antibody development: Guili Xu, Niliang Qian, Xin gao. In vivo efficacy study: Huilun Chu, Junping Lv. Pharmacokinetic study: Yunlong Liu, Lun Ou, Huilun Chu. In vitro study: Yujie Liu, Xiujie Pan, Guili Xu, Huilun Chu. Toxicity Study: Yanchuan Li, Huilun Chu. Analysis and interpretation of data: all authors. Writing of the manuscript: Huilun Chu, Guili Xu, Xin gao. All authors have read and approved the final version of the manuscript and consent to its publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request. For inquiries regarding data and materials, please contact Huilun Chu at Guangxi Ardeon Therapeutics Co., Ltd. (email: chuhl@ardeontx.com).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability and materials"}}]}}